Evidence map›Paper›PMID 31006040›Full record

ArticleMedical molecular morphology2019

Assessment of ApoC1, LuzP6, C12orf75 and OCC-1 in cystic glioblastoma using MALDI-TOF mass spectrometry, immunohistochemistry and qRT-PCR.

Petros Evangelou, Mathias Groll, Henry Oppermann, Frank Gaunitz, Christian Eisenlöffel, Wolf Müller, Klaus Eschrich, Anne Schänzer, Ulf Nestler

Open access · hybridAbstract read
In one paragraph

Article in Medical molecular morphology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Petros EvangelouDepartment of Neurosurgery, University Hospital Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Mathias GrollDepartment of Neurosurgery, University Hospital Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Henry OppermannDepartment of Neurosurgery, University Hospital Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Frank GaunitzDepartment of Neurosurgery, University Hospital Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany.
Christian EisenlöffelInstitute of Neuropathology, University Hospital Leipzig, Liebigstrasse 26, 04103, Leipzig, Germany.
Wolf MüllerInstitute of Neuropathology, University Hospital Leipzig, Liebigstrasse 26, 04103, Leipzig, Germany.
Klaus EschrichRudolf Schoenheimer Institute of Biochemistry, Medical Faculty, University of Leipzig, Johannisallee 30, 04103, Leipzig, Germany.
Anne SchänzerInstitute of Neuropathology, Justus Liebig University Giessen, 35392, Giessen, Germany.
Ulf NestlerDepartment of Neurosurgery, University Hospital Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany. ulf.nestler@medizin.uni-leipzig.de.ORCID http://orcid.org/0000-0002-2963-4344
University Hospital Leipzig · DEJustus-Liebig-Universität Gießen · DELeipzig University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass spectrometric analysis of glioblastoma cyst fluids has disclosed a protein peak with m/z 6424-6433. Among the proteins, potentially generating this peak are ApoC1 and LuzP6. To further elucidate protein expression of glioblastoma cells, we analyzed MALDI-TOF results of cyst fluid, performed immunohistochemistry and mRNA analysis. MALDI-TOF protein extraction from 24 glioblastoma cyst fluids was performed with a weak cation exchange. 50 glioblastoma samples were stained with two custom-made antibodies against LuzP6 and commercial antibodies against ApoC1, C12orf75 and OCC-1 and analyzed. For mRNA detection, 16 tissue samples were stored in RNAlater, extracted using the miRNeasy kit and reversely transcribed. For 12 patients, synopsis of results from all three examinations was possible. MALDI-TOF confirmed the peak at 6433 Da in 75% of samples. Immunohistochemically, LuzP6 was detected in 92% (LuzP6

Indexed as

Apolipoprotein C-IFemaleGlioblastomaHumansImmunohistochemistryMaleMiddle AgedNeoplasm ProteinsReverse Transcriptase Polymerase Chain ReactionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAPOC1 protein, humanApolipoprotein C-IC12orf75 protein, humanNeoplasm ProteinsApoC1C12orf75Cystic glioblastomaLuzP6MALDI–TOFMalignant gliomaOCC-1

Identifiers

PMID31006040
PMCPMC6885021
OpenAlexW2940380955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.